Clin2
NCT07788469Worth exploringNot yet recruiting

New drug to remove factor viii inhibitors in hemophilia a

Hemophilia A With Inhibitors

Treatments studied

Elranatamab

Part of Blood & lymphatic, Genetic & congenital clinical trials.

This study tests a new treatment called elranatamab to help your body get rid of the inhibitor that blocks factor VIII replacement therapy. The goal is to make standard hemophilia treatment work better for you.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are age 18 to 65.
  • You have moderate or severe hemophilia A (factor VIII level below 2%).
  • You have had a positive factor VIII inhibitor test at least twice, with your current level above 10 BU/mL.
  • You have not had cancer (other than certain skin cancers or cervical carcinoma in situ) in the last 5 years.
  • You do not have severe or ongoing infections, or an active infection requiring treatment within the past month.
  • You do not have hepatitis B, hepatitis C, HIV, or syphilis.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07437404Recruiting· Phase 3
Testing SCT800 for previously untreated severe hemophilia A

This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.

Beijing, Beijing Municipality
NCT05888870Recruiting· Phase 4
Testing a treatment for hemophilia A with inhibitor antibodies

This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.

Tianjin
NCT06111638Recruiting· Phase 2/Phase 3
Gene therapy for severe hemophilia A

This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.

Beijing, Beijing Municipality
NCT05454774Recruiting· Early Phase 1
Gene therapy for adults with severe hemophilia A

This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).

Tianjin, Tianjin Municipality
NCT07416526Recruiting· Phase 3
Testing NXT007 for hemophilia A without inhibitors

This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.

Aurora, Colorado
NCT04023019Recruiting
Hemophilia A trial for people with FVIII inhibitors

This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.

Atlanta, Georgia

Hear when a new Hemophilia A With Inhibitors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.